Editas医药 EDIT 深 沪
等待开盘 09-16 09:30:00 美东时间
2.67
-0.020
-0.74%
华盛通- 最 高2.789
- 今 开2.72
- 成交量 112.15万股
- 最 低 2.6031
- 昨 收 2.69
- 总市值 2.24亿
- 52周最高 3.80
- 市盈率 静 --
- 换手率 1.34%
- 52周最低 0.9101
- 委 比 -82.18%
- 总股本 8371.29万
- 历史最高 99.95
- 量 比 0.85
- 振 幅 6.91%
- 历史最低 0.9101
- 每 手 1
- 风险率 2.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
In the last three months, 4 analysts have published ratings on Editas Medicine ...
09-05 20:01
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
Editas Medicine announced the nomination of EDIT-401, an experimental gene editing therapy designed to significantly reduce LDL cholesterol (LDL-C) levels. Preclinical studies showed EDIT-401 achieved ~90% mean LDL-C reduction in non-human primates, surpassing standard therapies. The company aims to advance EDIT-401 to human proof-of-concept data by end of 2026 and has a strong cash position to support operations into the second quarter of 2027. ...
09-02 11:00
英伟达迎来一群劲敌
原标题：英伟达迎来一群劲敌 近期发布的超以太网（Ultra Ethernet，简称UE）1.0规范，为未来人工智能（AI）和高性能计算（HPC）系统定义了一套...
09-01 16:17
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
CAD Pharmaceuticals أعلنت شركة إديتاس ميديسين("", glands التي مقرها في كمبردج، ماساتشوستس، عن عقد ندوي patrols_ via-distance_ Online في التاسع من سبتمبر للكشف عن المرشح reimbursable_ developmounted chief. يمكن للمرتفقين الوصول إلى البث الحي والمتواجد عن طريق الرابط المذكور في محفوظات الموقع الالكتروني للشركة.}() 翻译成英文： Editas Medicine announced it will host a webinar on September 2 to reveal its lead in vivo development candidate. The live and ...
08-28 20:01
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine announced its participation in three upcoming healthcare conferences in September 2025, including one-on-one meetings and a fireside chat. These events will be held in Boston, MA, and New York, NY, with live webcasts available through the company’s website. Editas Medicine, a leader in gene editing focused on CRISPR/Cas12a and CRISPR/Cas9 systems, aims to develop transformative medicines for serious diseases. Access to the webcast...
08-27 13:00
VCREDIT Holdings Updates Nomination Committee Terms
VCREDIT Holdings Limited ( ($HK:2003) ) has shared an update. VCREDIT Holdings ...
08-25 23:09
Analysts Are Bullish on These Healthcare Stocks: Editas Medicine (EDIT), Tilray (TLRY)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-25 18:20
LENDINGTREE ANNOUNCES CLOSING OF $475 MILLION CREDIT FACILITY
New Financing Reduces Interest Expense, Removes Cumbersome Covenants, and Increases Operating Flexibility CHARLOTTE, N.C., Aug. 22, 2025 /PRNewswire/ -- LendingTree, Inc. (NASDAQ: TREE), the...
08-22 20:32
【华龙传媒】周报：AI商业落地实践，多场景应用与生态协同
（来源：华龙证券研究） 摘要： 百度AIDAY探讨AI商业落地：聚焦电商、游戏、可穿戴与具身智能。2025年8月12日，百度AIDAY开放日以...
08-19 22:31
POLARIS RZR PRO R FACTORY REIGNS SUPREME AT 2025 VEGAS TO RENO
Polaris-Supported Racer Mitch Guthrie Jr. and his RZR Pro R Factory Win UTV Overall MINNEAPOLIS, Aug. 18, 2025 /PRNewswire/ -- In a stunning display of skill, stamina, and precision, Polaris...
08-19 07:55
